Sign in

CRBP on Nasdaq

Corbus Pharmaceuticals

Logo: corbuspharma.com4

American pharmaceutical company based in Norwood, incorporated in Delaware1

In its 2026 annual report the company says: “Corbus Pharmaceuticals Holdings, Inc. is a clinical stage company focused on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways.”7 Its shares trade on Nasdaq under the symbol CRBP.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Jan 1, 2009Founded1

Compare with Aeglea BioTherapeutics, Rallybio or Neurogene Inc., or pick any stock.

  • TickerCRBP on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersNorwood1
  • Websitecorbuspharma.com
  • Incorporated inDE5
  • Business address500 River Ridge Drive, Norwood, Ma 020625
  • Filer categoryNon-accelerated filer, Smaller reporting company5
  • Legal formCorporation3
  • LEI529900MX6XCNZC7MM1553
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressc/o COGENCY GLOBAL INC., 850 NEW BURTON ROAD SUITE 201, 19904 Dover, United States3
  • Registered withDivision of Corporations, Department of State, 54519153

See how the biggest companies compare on our leaderboards

All references in this report to “Corbus,” the “Company,” “we,” “us,” or “our” mean Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates.7 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-100.0%Revenue growth, 20228
-128.4%Return on equity9
0.48×Debt to equity10
-$37.6MFree cash flow10

Financial statements

Revenue11128$0 in 2022
0$10.0M$20.0M$30.0M$40.0M2019: $36.1M$36.1M20192020: $3.9M$3.9M2020−89%2021: $881.7K$881.7K2021−78%2022: $0$02022
Operating income1112810-$39.8M in 2022−48% since 2019
-$150.0M-$100.0M-$50.0M02019: -$77.1M-$77.1M20192020: -$122.8M-$122.8M2020+59%2021: -$56.0M-$56.0M2021−54%2022: -$39.8M-$39.8M2022−29%
Net income1112810-$42.3M in 2022−41% since 2019
-$150.0M-$100.0M-$50.0M02019: -$71.5M-$71.5M20192020: -$111.3M-$111.3M2020+56%2021: -$45.6M-$45.6M2021−59%2022: -$42.3M-$42.3M2022−7%

Every line of the income statement as filed: the last 2 fiscal years, latest first.15

Period ending2025-12-312024-12-31
Research and development$70.1M$32.2M
General and administrative$15.2M$16.5M
Total operating expenses$85.3M$48.7M
Operating loss-$85.3M-$48.7M
Interest and investment income, net$5.5M$6.3M
Interest expense$0-$1.9M
Other income, net$1.2M$4.1M
Total other income, net$6.8M$8.5M
Net loss-$78.5M-$40.2M
Net loss per share, basic-$5.90-$3.68
Net loss per share of common stock diluted-$5.90-$3.68
Weighted average number of common shares outstanding, basic13.3M shares10.9M shares
Weighted average number of common shares outstanding, diluted13.3M shares10.9M shares
Net Income (Loss)-$78.5M-$40.2M
Change in unrealized (loss) gain on marketable debt securities-$88.0K$36.0K
Total other comprehensive (loss) income-$88.0K$36.0K
Total comprehensive loss-$78.6M-$40.2M

Compare Corbus Pharmaceuticals with another company

Corporate structure

Corbus Pharmaceuticals sits at the top of its group. 3 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Corbus Pharmaceuticals

  • Corbus Pharmaceuticals Norwood, Massachusetts, United States
    • Corbus International Limited Subsidiary · United Kingdom
    • Corbus Pharmaceuticals Australia Pty Ltd Subsidiary · Australia

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Corbus Pharmaceuticals reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.5M15 Dec 31, 2025$4.5M15 Dec 31, 2024+0.2%
Accumulated depreciation$4.3M15 Dec 31, 2025$4.1M15 Dec 31, 2024+5.7%
Property and equipment, net$159.0K15 Dec 31, 2025$385.0K15 Dec 31, 2024−58.7%
Operating-lease assets (leased space)$1.1M15 Dec 31, 2025$2.1M15 Dec 31, 2024−49.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$28.5M15 Dec 31, 2025$17.2M15 Dec 31, 2024+65.7%
Marketable securities, current$134.8M15 Dec 31, 2025$131.9M15 Dec 31, 2024+2.2%
Debt securities available for sale$134.8M15 Dec 31, 2025$131.9M15 Dec 31, 2024+2.2%

Properties, in its own words

Our principal offices are located at 500 River Ridge Drive, Norwood, MA 02062 and consists of 63,256 square feet of leased office space at December 31, 2025. The lease term for this office space ends on November 30, 2026.

Item 2 of the 10-K filed Mar 9, 2026.7

Leadership

Who has led Corbus Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

President

  1. Mark Tepper2014–2019

Chief operating officer

  1. Robert Paul Discordia2019–2020
  2. Craig Stuart Millian2022–2023
  3. Ian Hodgson2025–now
2010201520202025
Board members and other officers (18)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Corbus International Limited United Kingdom6
  • Corbus Pharmaceuticals Australia Pty Ltd Australia6
  • Corbus Pharmaceuticals, Inc. Delaware6

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • SAV Acquisition CorpJan 10, 2014 to Jan 10, 20145

Timeline

  1. Oct 15, 20268-K Regulation FD disclosure38
  2. Sep 14, 20268-K Regulation FD disclosure; Other events39
  3. Aug 6, 20268-K Results of operations; Regulation FD disclosure40
  4. Jul 6, 20268-K Entered a material agreement; Regulation FD disclosure41
  5. May 26, 20268-K Regulation FD disclosure; Other events42
  6. May 21, 20268-K Entered a material agreement; Executive or director change; Regulation FD disclosure43
  7. May 14, 20268-K Executive or director change; Shareholder vote; Regulation FD disclosure44
  8. May 12, 20268-K Results of operations; Regulation FD disclosure45
  9. Apr 16, 20268-K Executive or director change46
  10. Apr 14, 20268-K Regulation FD disclosure; Other events47
  11. Apr 7, 20268-K Executive or director change; Regulation FD disclosure; Other events48
  12. Mar 9, 20268-K Results of operations; Regulation FD disclosure49
  13. Jan 1, 2009Founded Founded1

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.90) a share, on Nov 12, 2025.50

When it reported results

  1. Aug 6, 2026Reported quarterly or annual results40
  2. May 12, 2026Reported quarterly or annual results45
  3. Mar 9, 2026Reported quarterly or annual results49
  4. Nov 12, 2025Reported quarterly or annual results51
  5. Aug 5, 2025Reported quarterly or annual results52
  6. May 6, 2025Reported quarterly or annual results53
  7. Mar 11, 2025Reported quarterly or annual results54
  8. Nov 7, 2024Reported quarterly or annual results55

Drug trials and FDA: coming up

  1. Nov 1, 2026Phase 1/2 trial readout expected Phase 1/2 trial of CRB-601 monoclonal antibody and Anti-PD-1 monoclonal antibody in Solid Tumor: primary completion expected Nov 1, 2026 (ClinicalTrials.gov NCT06603844).56
  2. Jan 16, 2027Phase 1/2 trial readout expected Phase 1/2 trial of CRB-701 and Anti-PD-1 in Solid Tumor, Adult: primary completion expected Jan 16, 2027 (ClinicalTrials.gov NCT06265727).57

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

313 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 81 major events, 111 insider forms, 38 large holders, 62 other. The latest 20:

  1. Oct 15, 20268-K EDGAR
  2. Sep 30, 2026SCHEDULE 13G EDGAR
  3. Sep 15, 20264 EDGAR
  4. Sep 14, 20268-K EDGAR
  5. Aug 17, 20264 EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 12, 20264 EDGAR
  8. Aug 10, 20264 EDGAR
  9. Aug 10, 20264 EDGAR
  10. Aug 7, 2026144 EDGAR
  11. Aug 7, 2026144 EDGAR
  12. Aug 7, 2026424B5 EDGAR
  13. Aug 6, 202610-Q EDGAR
  14. Aug 6, 20268-K EDGAR
  15. Aug 4, 20263 EDGAR
  16. Jul 27, 2026SCHEDULE 13G EDGAR
  17. Jul 27, 2026144 EDGAR
  18. Jul 6, 20268-K EDGAR
  19. Jun 17, 2026S-8 EDGAR
  20. Jun 11, 20264 EDGAR

The 313 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

44 open-market trades by officers, directors and large owners since October 2021: 16 buys and 28 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 14, 2026Ben YongDirectorSale2,000$7.84$15.7KForm 4
Aug 11, 2026Saxena Nishant CChief Business OfficerBuy2,600$9.63$25.0KForm 4
Aug 7, 2026Cohen YuvalChief Executive OfficerSale17,000$10.08$171.4KForm 4
Aug 7, 2026Moran Sean F.Chief Financial OfficerSale12,000$10.08$121.0KForm 4
Jun 10, 2026Kung WinstonDirectorSale2,026$7.91$16.0KForm 4
Jun 10, 2026Jenkins John KennethDirectorSale4,800$7.91$38.0KForm 4
Jun 10, 2026Altmeyer AnneDirectorSale2,412$7.91$19.1KForm 4
Jun 3, 2026Saxena Nishant CChief Business OfficerBuy9,000$7.58$68.2KForm 4
Jun 2, 2026Saxena Nishant CChief Business OfficerBuy4,500$7.33$33.0KForm 4
Mar 2, 2026Smethurst DominicChief Medical OfficerSale6,097$8.30$50.6KForm 4
Feb 17, 2026Hodgson IanChief Operating OfficerSale847$7.38$6.3KForm 4
Feb 13, 2026Moran Sean F.Chief Financial OfficerSale4,701$7.78$36.6KForm 4
Feb 13, 2026Cohen YuvalChief Executive OfficerSale13,871$7.78$107.9KForm 4
Feb 3, 2026Smethurst DominicChief Medical OfficerSale3,285$8.09$26.6KForm 4
Feb 3, 2026Hodgson IanChief Operating OfficerSale2,415$8.09$19.5KForm 4
Dec 11, 2025Chen Bihua10% ownerSale30,029$11.46$344.1KForm 4
Oct 27, 2025Cohen YuvalChief Executive OfficerSale8,973$17.14$153.8KForm 4
Oct 24, 2025Cohen YuvalChief Executive OfficerSale18,660$17.01$317.4KForm 4
Oct 24, 2025Moran Sean F.Chief Financial OfficerSale12,981$17.02$220.9KForm 4
Oct 20, 2025Altmeyer AnneDirectorSale1,060$20.50$21.7KForm 4

All 44 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Yuval Cohen$646.6K$3.8M77
2025Dominic Smethurst52$519.3K$1.8M77
2025Sean Moran68$481.1K$1.8M77
2024Chief Executive Officer$621.9K$4.2M77
2024Chief Medical Officer$408.9K$2.9M77
2024Chief Financial Officer$462.8K$2.4M77

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Cormorant Asset Management, LP2,344,971$22.0M1.1%No change
Orbimed Advisors LLC1,737,287$16.3M0.3%No change
BlackRock, Inc.1,331,135$12.5M0.0%+1,059,499
Aberdeen Group plc1,321,750$12.4M0.0%No change
Vanguard Capital Management LLC760,940$7.1M0.0%+26,834
Jones Hill Capital LP653,572$6.1M1.3%New
Prosight Management, LP650,000$6.1M1.1%−47,108
Stonepine Capital Management, LLC425,000$4.0M3.0%+41,538
Geode Capital Management, LLC423,374$4.0M0.0%+236,345
ADAR1 Capital Management, LLC421,787$4.0M0.2%+90,006
Diadema Partners LP301,264$2.8M1.1%−138,693
Susquehanna International Group, Llp293,203$2.8M0.0%−40,212
State Street Corp254,672$2.4M0.0%+185,800
Dimensional Fund Advisors LP190,214$1.8M0.0%+53,612
Exome Asset Management LLC184,914$1.7M1.1%−49,222
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.151,640$1.4M0.0%−8,822
Jane Street Group, LLC139,133$1.3M0.0%+65,940
Northern Trust Corp124,906$1.2M0.0%+83,402
Vanguard Fiduciary Trust Co112,397$1.1M0.0%+16,156
Vanguard Portfolio Management LLC111,302$1.0M0.0%+86,937
Renaissance Technologies LLC110,822$1.0M0.0%−236,176
DAFNA Capital Management LLC107,773$1.0M0.2%New
Citadel Advisors LLC92,154$864.4K0.0%−634,906
Advisory Services Network, LLC89,951$843.7K0.0%+89,937
Cantor Fitzgerald, L. P.80,196$752.2K0.0%+40,098

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Corbus Pharmaceuticals is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCorbus Pharmaceuticals Holdings, Inc.2
  • CIK0001595097
  • Employer ID (EIN)46-43480397
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company7
  • Incorporated inDelaware7
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address500 River Ridge Drive, Norwood, MA 020622
  • Phone617-963-01032
  • Shares outstanding19,341,293 as of Aug 4, 202614
  • Public float$67.8M as of Jun 30, 20257
  • AuditorEISNERAMPER LLP, Iselin, New Jersey PCAOB ID 274; no auditor attestation of internal control over financial reporting7
  • On EDGAR sinceJan 10, 20142
  • Filings805 in all: 4 (309), 8-K (178), SC 13G/A (46), 10-Q (36), 3 (27), SC 13G (23), 424B5 (16), 144 (14)2
    All 39 form types

    CORRESP (13), DEF 14A (13), S-8 (13), 10-K (12), 424B3 (12), DEFA14A (12), UPLOAD (12), EFFECT (9), SCHEDULE 13G/A (8), 8-K/A (6), S-3 (6), CT ORDER (5), ARS (4), PRE 14A (4), SCHEDULE 13G (4), D (3), 4/A (2), 8-A12G (2), POS AM (2), S-1/A (2), S-3/A (2), 10-K/A (1), 10-Q/A (1), 5 (1), 8-A12B (1), CERTNAS (1), DRS (1), DRS/A (1), DRSLTR (1), S-1 (1), S-3MEF (1)

  • Latest filingsAnnual report (10-K) Mar 9, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Apr 2, 2026
    Latest 8-K (8-K) Oct 15, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareCRBPNasdaq

From the cover page of the 10-K filed Mar 9, 2026 (Section 12(b) of the Exchange Act).7

Risk factors and legal proceedings

The risks Corbus Pharmaceuticals names in Item 1A of its 10-K filed Mar 9, 2026: 52 risks under these headings, as written.7

  • Risk Related to our Company and our Business
  • Risks Related to Our Business, Financial Position and Need for Capital
  • We are a biopharmaceutical company with a limited operating history.
  • We have incurred operating losses in each year since our inception and expect to continue to incur substantial losses for the foreseeable future. We may never become profitable or, if we achieve profitability, be able to sustain profitability.
  • Our cash, cash equivalents, or investments will only fund our operations for a limited time, and we will need to raise additional capital to support our development and commercialization efforts.
  • Risks Related to Product Development, Regulatory Approval, Manufacturing and Commercialization
  • Our success is dependent upon successful development of our drug candidates in our pipeline or that we may acquire. If we are unable to generate revenues from any product candidates, our ability to create stockholder value will be limited.
  • Drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
  • Reductions in staffing and funding at FDA and other federal agencies could cause delays in the development and approval of our products.
  • If we are not able to obtain any required regulatory approvals for our drug candidates, we will not be able to commercialize our product candidates and our ability to generate revenue will be limited.
  • Changes in product candidate manufacturing or formulation may result in additional costs or delay.
  • Approval may be delayed or denied because we cannot satisfy FDA’s Chemistry, Manufacturing and Control Requirements.
The other 42 risks
  • Even if we receive regulatory approval for our drug candidates, we still may not be able to successfully commercialize any of our products, and the revenue that we generate from sales, if any, may be limited.
  • Even if we obtain marketing approval for our drug candidates, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, our drug candidates could be subject to labeling and other restrictions and withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our drug candidates.
  • Our product candidates may cause undesirable side effects or have other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in post-approval regulatory action.
  • We have entered into, and may in the future enter into, collaboration agreements for the licensing, development, and ultimate commercialization of some of our drug candidates. In such cases, we will depend greatly on our third-party collaborators to license, develop and commercialize such drug candidates, and they may not meet our expectations.
  • We face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.
  • Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug candidates and affect the prices we may obtain.
  • Our future growth depends, in part, on our ability to enter into and succeed in markets outside of the U.S., where we may choose to rely on third-party collaborations and will be subject to additional regulatory and commercial burdens, risks and other uncertainties.
  • If we market our drug candidates in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties.
  • We are, and will be, completely dependent on third parties to manufacture our drug candidates, and our commercialization of our drug candidates could be halted, delayed or made less profitable if those third parties fail to obtain manufacturing approval from the FDA or comparable foreign regulatory authorities, fail to provide us with sufficient quantities of our drug candidates or fail to do so at acceptable quality levels or prices.
  • There are risks associated with scaling up manufacturing to commercial scale. If our contract manufacturers are unable to manufacture our drug candidates on a commercial scale, this could potentially delay regulatory approval and commercialization or materially adversely affect our results of operations.
  • We expect that we will rely on third parties to assist us in conducting clinical trials for our drug candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business would be substantially harmed.
  • Any termination or suspension of or delays in the commencement or completion of any necessary studies of our drug candidates for any indications could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
  • We may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates.
  • Third-party coverage and reimbursement and health-care cost containment initiatives and treatment guidelines may constrain our future revenues.
  • Our collaboration partners are conducting and may intend to conduct additional clinical trials for certain of our drug candidates at sites outside the U.S., and the FDA may not accept data from trials conducted in such locations or may require additional U.S.-based trials.
  • Risks Relating to Our Intellectual Property Rights
  • It is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights.
  • We have in-licensed a portion of our intellectual property, and if we fail to comply with our obligations under these arrangements, we could lose such intellectual property rights or owe damages to the licensor of such intellectual property.
  • Our product candidates may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development and commercialization efforts.
  • We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.
  • We are, and may become, subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets that, regardless of merit, could result in significant expense and loss of our intellectual property rights.
  • We may be subject to claims challenging the inventorship of our patents and other intellectual property.
  • General Company-Related Risks
  • We will need to grow the size of our organization, and we may experience difficulties in managing this growth.
  • Future capital raises may dilute our existing stockholders’ ownership and/or have other adverse effects on our operations.
  • If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. In addition, the loss of the services of certain key employees would adversely impact our business prospects.
  • If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our drug candidates.
  • We may acquire businesses, assets, or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions.
  • Significant disruptions of information technology systems or breaches of data security could materially adversely affect our business, results of operations and financial condition.
  • Changes in geopolitical conditions, U.S.-China trade relations and other factors beyond our control may adversely impact our business and operating results.
  • Disruptions in the global economy and supply chains may have a material adverse effect on our business, financial condition and results of operations.
  • Adverse global conditions, including economic uncertainty, may negatively impact our financial results.
  • Risks Related to our Common Stock
  • An active, liquid trading market for our common stock may not be sustained.
  • We are currently listed on The Nasdaq Capital Market. If we are unable to maintain listing of our securities on The Nasdaq Capital Market or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain financing could be impaired and it may be more difficult for our stockholders to sell their securities.
  • Our failure to maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of our common stock.
  • The market price of our common stock may be significantly volatile.
  • Future sales of shares by existing stockholders could cause our stock price to decline.
  • We do not currently intend to pay dividends on our common stock in the foreseeable future, and consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock.
  • If we fail to maintain effective internal controls, we may not be able to report financial results accurately or on a timely basis, or to detect fraud, which could have a material adverse effect on our business or share price.
  • We may be unable to complete our analysis of our internal controls over financial reporting in a timely manner, or these internal controls may not be determined to be effective, which may adversely affect investor confidence in our company and, as a result, the value of our common stock.
  • Upon dissolution of our company, you may not recoup all or any portion of your investment.
  • Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
  • Legislation or other changes in U.S. tax law could adversely affect our business and financial condition.
  • Our certificate of incorporation, as amended, allows for our board to create new series of preferred stock without further approval by our stockholders, which could adversely affect the rights of the holders of our common stock.

Legal proceedings

We are not currently subject to any material legal proceedings. However, we may from time to time become a party to various legal proceedings arising in the ordinary course of our business.

The opening of Item 3, Legal Proceedings.7

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77